Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02125019 · ClinicalTrials.gov registry record
Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 62
- Enrollment target
NCT02125019: Completed study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT02125019 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02125019 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 62 participants
- Enrollment target
Study Summary
Longitudinal Evaluation of Taxane induced neuropathy in early stage breast cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2013-12-04 |
| Est. Completion | 2018-05-14 |
What the finished NCT02125019 record still lists
NCT02125019 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 62 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02125019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02125019 about?
NCT02125019 is a clinical study titled "Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer". Longitudinal Evaluation of Taxane induced neuropathy in early stage breast cancer.
What is the current status of trial NCT02125019?
This trial is currently completed. The enrollment target is 62 participants. The study started on 2013-12-04. Estimated completion is 2018-05-14.
Who is sponsoring clinical trial NCT02125019?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI